July 16, 2026 Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update Read More
June 29, 2026 Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease Read More
June 10, 2026 Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit Read More
May 26, 2026 Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026 Read More
May 11, 2026 Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update Read More
April 24, 2026 Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026 Read More
March 26, 2026 Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update Read More
March 18, 2026 Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 Read More
March 12, 2026 Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update Read More
February 19, 2026 Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference Read More
January 7, 2026 Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week Read More
January 6, 2026 Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287 Read More
